As the regulatory landscape continues to evolve, 2025 is a pivotal year for legal leaders in biopharma. The 6th In-House Impact: Biopharma Summit is your exclusive opportunity to unite with top legal minds from Takeda, Kura Oncology, Neurocrine Biosciences, and more to tackle today's most pressing challenges-tariffs, financing, M and A strategy, and beyond. Tailored for General Counsels and Chief Legal Officers at drug development companies, this intimate, peer-led summit empowers you to elevate legal as a business-critical function. Learn how in-house teams are adapting to economic volatility, harnessing new legal tech, and navigating cross-functional leadership demands, all while building a valuable network of peers.